αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform
Biotechnology and Bioengineering · 2023-04 · 120 (4) · 1108-1119
DOI: 10.1002/bit.28313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 03.01.2023. Verfasst von Jingru Che und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Glioblastoma, Glioma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, Pelotonia.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most common form of brain cancer. Even with aggressive treatment, tumor recurrence is almost universal and patient prognosis is poor because many GBM cell subpopulations, especially the mesenchymal and glioma stem cell populations, are resistant to temozolomide (TMZ), the most commonly used chemotherapeutic in GBM. For this reason, there is an urgent need for the development of new therapies that can more effectively treat GBM. Several recent studies have indicated that high expression of connexin 43 (Cx43) in GBM is associated with poor patient outcomes. It has been hypothesized that inhibition of the Cx43 hemichannels could prevent TMZ efflux and sensitize otherwise resistance cells to the treatment. In this study, we use a three‐dimensional organoid model of GBM to demonstrate that combinatorial treatment with TMZ and αCT1, a Cx43 mimetic peptide, significantly improves treatment efficacy in certain populations of GBM. Confocal imaging was used to visualize changes in Cx43 expression in response to combinatorial treatment. These results indicate that Cx43 inhibition should be pursued further as an improved treatment for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, The Ohio State University, Columbus, Ohio, USA.
- The Ohio State University and Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
- Biomedical Sciences Graduate Program, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Dorothy M. Davis Hearth and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA.
- Department of Radiation Oncology, James Cancer Hospital and Comprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, Ohio, USA.
- Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Aleksander Skardal
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- Pelotonia
- National Institutes of Health
- American Cancer Society
- College of Engineering, Ohio State University
- Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Zitieren
APA
Che, J., DePalma, T. J., Sivakumar, H., Mezache, L. S., Tallman, M. M., Venere, M., Swindle-Reilly, K., Veeraraghavan, R., & Skardal, A. (2023). αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform. Biotechnology and Bioengineering, 120(4), 1108-1119. https://doi.org/10.1002/bit.28313
Vancouver
Che J, DePalma TJ, Sivakumar H, Mezache LS, Tallman MM, Venere M, et al. αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform. Biotechnology and Bioengineering. 2023;120(4):1108-1119. doi:10.1002/bit.28313
BibTeX
@article{Che2023,
author = {Che, Jingru and DePalma, Thomas J and Sivakumar, Hemamylammal and Mezache, Louisa S and Tallman, Miranda M and Venere, Monica and Swindle-Reilly, Katelyn and Veeraraghavan, Rengasayee and Skardal, Aleksander},
title = {αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform},
journal = {Biotechnology and Bioengineering},
year = {2023},
volume = {120},
number = {4},
pages = {1108--1119},
doi = {10.1002/bit.28313}
}
EUVIMED